{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:40:37Z","timestamp":1787020837981,"version":"build-2736575974"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"DOI":"10.1186\/s13256-024-04905-5","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T13:16:54Z","timestamp":1737379014000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Management of chimeric antigen receptor T-cell-related toxicity of a patient affected by cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, followed by an intestinal perforation: a case report"],"prefix":"10.1186","volume":"19","author":[{"given":"G.","family":"Menardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Castellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Castellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. E.","family":"Bersia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Grande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Fraternali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Massaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Fruttero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,20]]},"reference":[{"key":"4905_CR1","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1182\/blood-2019-126064","volume":"134","author":"ML Wang","year":"2019","unstructured":"Wang ML, Munoz J, Goy A, et\u00a0al. KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in patients (Pts) with relapsed\/refractory (R\/R) mantle cell lymphoma (MCL): results of the phase 2 ZUMA-2 study. Blood. 2019;134:754.","journal-title":"Blood"},{"issue":"1","key":"4905_CR2","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","volume":"32","author":"ML Schubert","year":"2021","unstructured":"Schubert ML, Schmitt M, Wang L, Ramos CA, Jordan K, M\u00fcller-Tidow C, et\u00a0al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol. 2021;32(1):34\u201348.","journal-title":"Ann Oncol"},{"issue":"2","key":"4905_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001511","volume":"8","author":"MV Maus","year":"2020","unstructured":"Maus MV, Alexander S, Bishop MR, Brudno JN, Callahan C, Davila ML, et\u00a0al. Society for immunotherapy of cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J Immunother Cancer. 2020;8(2): e001511.","journal-title":"J Immunother Cancer"},{"issue":"27","key":"4905_CR4","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.19.02104","volume":"38","author":"LJ Nastoupil","year":"2020","unstructured":"Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, et\u00a0al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma results from the US lymphoma CAR T consortium. J Clin Oncol. 2020;38(27):3119\u201328.","journal-title":"J Clin Oncol"},{"issue":"10","key":"4905_CR5","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","volume":"22","author":"SJ Schuster","year":"2021","unstructured":"Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, et\u00a0al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22(10):1403\u201315.","journal-title":"Lancet Oncol"},{"key":"4905_CR6","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, et\u00a0al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531.","journal-title":"N Engl J Med"},{"key":"4905_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, et\u00a0al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45.","journal-title":"N Engl J Med"},{"issue":"10","key":"4905_CR8","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","volume":"28","author":"E Bachy","year":"2022","unstructured":"Bachy E, Le Gouill S, Di Blasi R, Sesques P, Manson G, Cartron G, et\u00a0al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med. 2022;28(10):2145\u201354.","journal-title":"Nat Med"},{"issue":"1","key":"4905_CR9","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.cell.2020.08.022","volume":"183","author":"KR Parker","year":"2020","unstructured":"Parker KR, Migliorini D, Perkey E, Yost KE, Bhaduri A, Bagga P, et\u00a0al. Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies. Cell. 2020;183(1):126-142.e17.","journal-title":"Cell"},{"key":"4905_CR10","unstructured":"Yescarta (axicabtagene ciloleucel) suspension for intravenous infusion. US Food and Drug Administration (FDA) product information. US National Library of Medicine. 2021. https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=9b70606e-b99c-4272-a0f1-b5523cce0c59&type=display. Accessed 5 April 2021."},{"issue":"6","key":"4905_CR11","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, et\u00a0al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med giugno. 2018;24(6):739\u201348.","journal-title":"Nat Med giugno"},{"issue":"13","key":"4905_CR12","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1182\/bloodadvances.2020002328","volume":"4","author":"P Strati","year":"2020","unstructured":"Strati P, Ahmed S, Kebriaei P, Nastoupil LJ, Claussen CM, Watson G, et\u00a0al. Clinical efficacy of anakinra to mitigate CAR T-cell therapy\u2013associated toxicity in large B-cell lymphoma. Blood Adv. 2020;4(13):3123\u20137.","journal-title":"Blood Adv"},{"key":"4905_CR13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.7566","author":"C Oliai","year":"2021","unstructured":"Oliai C, Crosetti A, De Vos S, Eradat H, Mead MD, Larson SM, et\u00a0al. IL-1 receptor antagonist for prevention of severe immune effector cell-associated neurotoxicity syndrome. J Clin Oncol. 2021. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.7566.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4905_CR14","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s40744-016-0037-z","volume":"3","author":"S Monemi","year":"2016","unstructured":"Monemi S, Berber E, Sarsour K, Wang J, Lampl K, Bharucha K, et\u00a0al. Incidence of gastrointestinal perforations in patients with rheumatoid arthritis treated with tocilizumab from clinical trial, postmarketing, and real-world data sources. Rheumatol Ther. 2016;3(2):337\u201352.","journal-title":"Rheumatol Ther."},{"issue":"3","key":"4905_CR15","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","volume":"33","author":"PJ Hayden","year":"2022","unstructured":"Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C, et\u00a0al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol Marzo. 2022;33(3):259\u201375.","journal-title":"Ann Oncol Marzo"},{"key":"4905_CR16","unstructured":"SIE: Italian society of hematology. Anti-CD19 CAR-T cell therapy in aggressive B lymphomas: SIE, SIDEM, GITMO recommendations. National system guidelines of the superior institute of health. National guidelines system. 2023."},{"issue":"8","key":"4905_CR17","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40264-022-01194-z","volume":"45","author":"M Fusaroli","year":"2022","unstructured":"Fusaroli M, Isgr\u00f2 V, Cutroneo PM, Ferrajolo C, Cirillo V, Del Bufalo F, et\u00a0al. Post-marketing surveillance of CAR-T-Cell therapies: analysis of the FDA adverse event reporting system (FAERS) database. Drug Saf agosto. 2022;45(8):891\u2013908.","journal-title":"Drug Saf agosto"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-024-04905-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-024-04905-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-024-04905-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T13:16:57Z","timestamp":1737379017000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-024-04905-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,20]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4905"],"URL":"https:\/\/doi.org\/10.1186\/s13256-024-04905-5","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,20]]},"assertion":[{"value":"16 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27"}}